Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 8,445 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolism Disorder, Glucose Clear all
Completed Phase 2Phase 3 Interventional

Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study

NCT04409795
View directory record Official record
Conditions
Type 1 Diabetes, Monogenic Diabetes
Interventions
Metformin Extended Release Oral Tablet, Sitagliptin
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
Up to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Not applicable Interventional

Impact of Food as Medicine Glycemic Control at Two Large Academic Medical Centers

NCT07748286
View directory record Official record
Conditions
Diabetes (DM), Nutrition
Interventions
Food as Medicine Eskenazi, Indiana Health NourishedRX
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes

NCT03046927
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Ergocalciferol, Placebo
Drug · Other
Lead sponsor
Benjamin U. Nwosu, MD
Other
Eligibility
10 Years to 21 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

NCT02229227
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide, Insulin Glargine and Insulin Lispro
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
39
States / cities
Searcy, Arkansas • Huntington Beach, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Not applicable Interventional Results available

Translating the DPP Into the Community

NCT00302042
View directory record Official record
Conditions
Prediabetic State, Overweight, Obesity
Interventions
Brief counseling plus group diabetes prevention in community, Brief Counseling for pre-diabetes alone
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

NCT04865770
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Chronic Kidney Disease
Interventions
Semaglutide, Placebo (Semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • National City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Phase 1 Interventional

Stem Cell Therapy for Chronic Kidney Disease

NCT04869761
View directory record Official record
Conditions
Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
Interventions
Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
Drug
Lead sponsor
LaTonya J. Hickson
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 22, 2026, 2:44 AM EDT
Completed No phase listed Observational

Identifying Risk for Diabetes and Heart Disease in Women

NCT01809288
View directory record Official record
Conditions
Obesity, Insulin Resistance, Triglycerides, Diabetes
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years to 65 Years · Female only
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Phase 2 Interventional

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

NCT00085969
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 22, 2026, 2:44 AM EDT
Not listed No phase listed Observational

Accuracy of Blood Glucose Detection by Diabetes Alert Dogs

NCT02126605
View directory record Official record
Conditions
Type I Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
6 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

NCT02981966
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 22, 2026, 2:44 AM EDT
Withdrawn Not applicable Interventional

Developing a Model to Predict Inpatient Hypoglycemic Episodes

NCT05989256
View directory record Official record
Conditions
Hypoglycemic Events, Hyperglycemic Therapy
Interventions
EndoTool, glucose management team, standard of care glucose management
Diagnostic Test · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 22, 2026, 2:44 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

NCT07400653
View directory record Official record
Conditions
Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2, Type 2 Diabetes
Interventions
PF-08653944, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
55
States / cities
Anaheim, California • Canoga Park, California • Cerritos, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 2:44 AM EDT
Completed No phase listed Observational

Assess Measurements of Wireless Cardiac Output Device

NCT02252757
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
CoVa
Device
Lead sponsor
Aventyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

NCT00637273
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
51
States / cities
Peoria, Arizona • Artesia, California • Concord, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Not applicable Interventional Results available

The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)

NCT03591354
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, t:slim X2 with Basal-IQ & Dexcom G6 CGM
Device
Lead sponsor
University of Virginia
Other
Eligibility
14 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 22, 2026, 2:44 AM EDT
Terminated No phase listed Observational

Factors Involved in Obesity-related Inflammation and Insulin Resistance

NCT01173705
View directory record Official record
Conditions
Obesity, Insulin Resistance, Inflammation
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 22, 2026, 2:44 AM EDT
Terminated Not applicable Interventional

Exercise Training and Metabolic Flexibility in Prediabetes

NCT04051229
View directory record Official record
Conditions
PreDiabetes, Sedentary Lifestyle
Interventions
6-week exercise training program, Standardized isoenergetic high fat diet
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Phase 4 Interventional Results available

Incretins in Impaired Fasting Glucose

NCT00364377
View directory record Official record
Conditions
Pre-diabetes
Interventions
Sitagliptin, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes

NCT00896077
View directory record Official record
Conditions
Healthy, Type 1 Diabetes
Interventions
Lisofylline
Drug
Lead sponsor
DiaKine Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 22, 2026, 2:44 AM EDT
Completed Not applicable Interventional

Empowering Rural African American Women and Communities to Improve Diabetes Outcomes

NCT01806194
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lifestyle Counseling, Educational Control Arm
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
19 Years to 75 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 22, 2026, 2:44 AM EDT
Recruiting Not applicable Interventional

OASIS: Peer Support for T2DM in Appalachia (Peer Participant)

NCT06336122
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Peer Coach Training - Weekly, Peer Coach Training - Biweekly
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bowling Green, Kentucky • Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 2:44 AM EDT
Completed No phase listed Observational

The Influence of Non-Caloric Artificial Sweeteners on Youth With Type 1 Diabetes

NCT03889522
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Bioelectrical Impedance Analysis, Total Body Dual-energy X-ray Absorptiometry, Blood draw
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 22, 2026, 2:44 AM EDT